Home/Pipeline/seRNA 002

seRNA 002

Lung Cancer

PreclinicalActive

Key Facts

Indication

Lung Cancer

Phase

Preclinical

Status

Active

Company

SRTD biotech

About SRTD biotech

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Viral Diseases

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active